Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No one will challenge me? Lol! Frankly I expected better from some of you! You should be telling me how management is actually the Swiss mafia, and there their sole purpose is to separate the shareholders from their money. And, telling how those large Swiss investors will make large sums of money with a plummeting PPS. The truly funny thing is, a couple of years ago we were begging for investors to put a few million in the pot keep the company alive. Now the company is alive and breathing, all that is left is test results!! Can this company save lives? Can they convince a major player to sign on? I think they can. If you don’t think so, punch out and look for life on another planet :) ok, i have had three glasses of wine with my steak lol
Contrary to popular belief, OXBT is not dead! The success or failure of the company always has, and always will ride on the back of oxycyte. I will not sit here and say that the current situation is making me happy, because it's not.
The PPS will rise and fall with each move that management makes, but in the final analysis, the results of testing will determine the value of this company. I bought a bunch of shares between 7-12 cents back when the company was weeks away from shutting off the lights and closing the doors. I believe that we are in far better shape today then we were then.
How do i see the company today? I still have faith in the products, but much less faith in management. Overall, i see this as a chance to get some additional shares at a value price. I believe this for one reason, I strongly believe that the results of oxycyte's testing will drive the price up significantly. Buy or sell as you gut tells you, and good luck to all.
DURHAM, N.C., Apr 22, 2010 (GlobeNewswire via COMTEX) --Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) today announced that the company has begun shipping its newly formulated Dermacyte(TM) Oxygen Concentrate to customers who pre-ordered this revolutionary beauty and skin care product on-line. Beginning this week, there is no longer a waiting period for order fulfillment and customers can select a shipping time-frame such as 3-5 days, or 1-2 days. Shipping rates will vary accordingly. Retail orders can be placed on the newly designed secure website at www.BuyDermacyte.com.
"Preorder sales for Dermacyte Oxygen Concentrate are encouraging and many orders are from repeat customers who purchased our product last fall during the market testing phase," said Chris Stern, company chairman and CEO. "The product now being shipped has an improved formulation and shows the new brand design and packaging that future Dermacyte products will feature, most notably the eye cream that we expect to introduce this summer."
Dermacyte Oxygen Concentrate is a scientifically designed, proprietary concentrate designed to enhance oxygen delivery to skin. It is the first product in a broad and diverse cosmetic line currently under development by the Oxygen Biotherapeutics. It uses our patented Oxycyte Technology, scientifically designed to enhance oxygen delivery to tissues, such as skin. Some potential benefits of increased oxygenation to the skin include a decrease in the appearance of fine lines, wrinkles and dryness.
Oxygen is essential for radiant, young-looking skin. It assists in the production of collagen and elastin, as well as with skin repair and regeneration. As we age, the body's ability to deliver oxygen to dermal tissue deteriorates. A lack of oxygen at the cellular level can cause skin to age prematurely, increasing the appearance of fine lines and age spots, making skin look dry and dull. A boost in oxygen may enhance the overall appearance and feel of your skin, leaving it smoother and healthier-looking.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product called Oxycyte(TM) that is being formulated for both intravenous and topical delivery for conditions including but not limited to traumatic brain injury, decompression sickness and topical wounds, as well as for personal skin care. More information is available at www.oxybiomed.com.
The Oxygen Biotherapeutics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7277
Our management team will ultimately be measured by the license agreements they can negotiate. I like the path we are one and I like the fact that we have many potential revenue streams. 2010 is shaping up to be the make or break year; either management delivers, or they fail and we are consumed by our burn-rate. The back-and-forth debate with the pariahs has reached a state of complete psychosis. The debate stopped being about the company a long time ago and has morphed into a pile of personal BS. The only thing that will remove the discussion from the kindergarten sandbox and move it to the level of an adult investor forum will be the success or failure of the company. I just hope one of those options happens soon, I’m getting really bored with the “groundhog day” debate. Luckily, the weather is turning into favorable boating weather, so I can drink many cold ones on the water while waiting for OXBT to reach its potential. I suggest some of you do the same, Happy spring everyone :)
I agree the news is nothing special, but i dont know about the PPS. Nothing will surprise me today up or down.
Today should be interesting. I believe yesterday was an anomaly; the news simply wasn’t strong enough to justify the jump. I still think that news is coming down the road. I suspect we will give some back today, but it was great to see some volume. The cream needs a license agreement to have any real impact.
Retired, i totally agree with all of your points! I will add one comment; if anyone feels that someone on this board has zero credibility, please just ignore them. Dont worry that their misinformation will affect anyone or anything, it wont. The company's progress will determine the PPS not posters on this board. Just simply ignore them. Good luck to all !!!
OXBO is clearly on the right path. Time will tell who is right. Some members are here just for the antisocial games, I strongly recommend just ignoring them. By responding in any why, you just feed the childish behavior. Sit back relax and enjoy the ride. All things will work themselves out in time :)
OXBO's performance actually has little to do with it anymore, those efforts are entirely personal. It just the same recycled anti-OXBO BS time and time again. Some are here just to play games, while others appreciate the diversity of opinion, and the occasional sanity check. I recommend ignoring the game players. OXBO will succeed or fail, the PPS will dance, and games will be played, but nothing that happens on this board will have any effect what so ever.
BTW Retired, i read all you posts very carefully and appreciate your efforts
seeray, i placed an order this morning :D
no way, she's mine :D dermacyte is for everyone else
Well, I now know what i'm buying everyone for christmas http://buydermacyte.com/
Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced its expanded product development plan.
The new clinical development pipeline now encompasses seven indications for the Oxycyte(TM) emulsion: Traumatic Brain Injury, Carbon Monoxide Poisoning, Surgical Iatrogenic Air Embolism, Spinal Cord Injury, Organ Preservation, Decompression Sickness, and Sickle Cell Crisis. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.
In the topical product area, the first use of the Dermacyte Gel is for a cosmetic line that is now available for pre-orders via the BuyDermacyte.com website with product shipment expected in about four weeks. The company plans to expand the cosmetic line into additional skin care products during 2010.
The topical pipeline includes six additional topical indications in development for the Oxycyte Gel. These include treatment for Wounds, Burns, Acne, Rosacea, Cell Treatment after Radiation Therapy, and Erectile Dysfunction.
Two other indications in development are based on Oxycyte compound in it's clear liquid form. They are the liquid ventilation device VitaVent, and Deep Immersion Fluorocarbon Treatment for severe burns.
"We have put together a product development plan that no longer depends on just one drug use indication with all of the associated risks and uncertainties. We now have four strategic pillars: Cosmetic with Dermacyte and related products, Topical Applications including wound care, Clinical Applications including TBI, and Devices including our VitaVent invention," said Company Chairman and CEO Chris J. Stern.
"Our clinical and topical development lines now include fifteen important potential applications. Before the end of the year, we plan to file an IND with the U.S. FDA for Oxycyte emulsion as a treatment for Carbon Monoxide poisoning. In addition, we plan to expand our cosmetic line rapidly in 2010. It's all part of our strategy to become a multi-product company with a clearly visible path for growth."
Slides outlining the development plan were presented at the company's shareholder meeting on Oct. 19, 2009. A replay of the webcast of that meeting may be found on the investor relations section of the company website. The replay will be archived for 90 days.
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has developed a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(TM)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications which are being marketed under the Dermacyte name. More information is available at www.oxybiomed.com.
Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements by Oxygen Biotherapeutics, Inc. that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include those referring to the timing of the shipment of Dermacyte Cosmetic Gel to customers and plans to expand the cosmetic product line in 2010 as well as plans for filing an IND with the U.S. FDA for Oxycyte emulsion as a treatment for Carbon Monoxide poisoning. There can be no assurance that those plans and expectations will be realized in the estimated time frame or at all. Additional information concerning these and other risk factors affecting Oxygen Biotherapeutics, Inc.'s business can be found in the company's public periodic filings with the Securities and Exchange Commission, which are available via www.oxybiomed.com. Oxygen Biotherapeutics, Inc. disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
SOURCE Oxygen Biotherapeutics, Inc.
http://www.oxybiomed.com
I wish I was going, but the my employer has different plans for me. I would love to actually meet some of you--even the pariah!
Retired, not sure what happened there,,,,,i was attempting to point out that a topical license agreement would be a noteworthy milestone and according to CS, is due in 09.
Come on blimper, he is 1 day old, one of your buddies from yahoo no doubt :)
King, Who is ignoring reality? The fact of the matter is that OXBO has never completed a R/S before so there is no data available to statistically evaluate the probability of success or failure. Each R/S has it’s own unique characteristics, and MOST R/S’s are executed by failing companies to prevent de-listing, so it easy to say that MOST fail—no wonder. Please feel free to use any data you want in your analysis, but when you post your opinion on a message board don’t e surprised if someone disagrees, especially when you are wrong. Statistically speaking, OXBO is one of one, and there are no other data points that are relevant. Have a great weekend.
Yes, but that “if” Pendulum swings both ways.
Hypothetical: What if, immediately after the R/S OXBO announces a significant milestone is reached? What if management is actually competent, and acting in the best interest of shareholders? What if they are simply doing what they need to do to get up-listed sooner rather then later? What if they have a plan to succeed with this R/S?
I just thought I would pose a different possibility, to the gloom and doom, massive dilution scenarios that are tossed around as though they were already part of OXBO history.
Personally, I believe the former is far more likely.
Oh, and please stop the madness (BS), many of you have pointed to other companies as R/S examples, none of them were OXBO and their performance cannot be held up as evidence of OXBO’s post R/S performance. They are all empty comparisons and mean NOTHING, so do try to get over it.
Good luck to you Seanman.
Fine, Its simple,,,,,all the news is based on what will happen IF the product works and gets approved.
All the news describes potential! When REAL news occurs, meaning proof that it works, you will see the stunning returns you are expecting. Until then just relax and enjoy all the funny posts :)
OMG, Obviously another ploy from a corrupt management team to distract voters from the R/S. But, it wont matter anyway because the entire company will be given to the Swiss Mafia anyway. The sky is falling and massive dilution is imminent……RUN, RUN for your lives.......
Please note the feeble attempt at sarcasm ;)
Have a great day
Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: OXBO) today announced that the company has submitted a patent application for a new invention that uses Oxycyte(R) perfluorocarbon to deliver oxygen as a first aid treatment for victims of heart attacks and strokes. Oxycyte is the Company's perfluorocarbon (PFC) therapeutic oxygen carrier.
The invention provides an immediate supply of Oxycyte and oxygen to the victim of a heart attack or stroke until medical help is available. It may be easily used by a person who has suffered a heart attack or stroke, but is still conscious, without the assistance of another. It may also be used easily by someone who cannot adequately perform CPR in order to assist someone who is unconscious.
By safely combining Oxycyte and oxygen in a device without pressure, and administering both together with the help of a self-propelled compressor, Oxycyte is able to absorb and carry into the victim's lungs an oxygen load that is 50 times greater than what the same volume of blood is able to carry. The concept of this invention is to administer oxygen-enriched Oxycyte through the lungs to reach oxygen-deprived tissues even when circulation is obstructed and/or a person has stopped breathing.
"This exciting new invention builds on our other intellectual property and gives us a way to leverage even greater value from our key product, Oxycyte. We've already named the invention Vitavent(TM). Ultimately, I see this device being sold over the counter and present wherever there is a defibrillator as well as in any home where there is concern about a potential heart attack or stroke for a loved one," said Chris Stern, company chairman and CEO. "We are already working on the market prototypes and intend to file a new device application with the FDA as soon as possible."
"With Vitavent, we now have a fourth pillar for our business strategy. It joins our cosmetic application, Dermacyte(TM), which we intend to launch in Q4; Wundecyte(TM), our wound care device and application; and our clinical compound Oxycyte, which is now in a Phase II-b clinical trial for Traumatic Brain Injury," said Stern.
Bing, I’ll try to explain, but let me start be saying that this is all a risk, Biotech Penny stock are inherently risky, and I accept that.
Now for my reasoning; After reading all the various opinions on this and other boards, and looking at this from all angles, I have concluded that it all boils down to two things.
1)Do I believe in the product (Oxycyte, in all of its manifestations)?
2)Do I trust OXBO to manage the product in a way that will maximize the value of my stock?
If I answer “NO” to either on of those questions it is time to sell my stock and move on. From what I’m reading many love oxycyte (yes to the 1st question) but believe OXBO management to be crooks who are up to no good (no to the 2nd question). My question to them is, what the hell are you doing holding a stock with a corrupt and inept management team?
Some other random points:
Two summers ago this company was nearly dead, they desperately needed money and the PPS was 7 cents. I was faced with the same decision then, (questions 1 and 2) and I answered yes to both questions and bought over 400k shares.
I think to be up-listed BEFORE Oxycyte hits big will be a huge advantage.
Having a committed large investor, Vatea, in our camp is a plus, not a negative. Two summers ago the addition of Vatea would have been that best news possible.
Testing Oxycyte costs big money, the grants are wonderful, but they are not enough. Should OXBO buy lottery tickets? Or, be prepared to dilute as needed based on a position of strength.
Just some thoughts,,,,,let the public stoning begin :)
add another 500k yes
There is simply no point in analyzing other R/S companies. Their success or failure has NO relevance to OXBO—NONE. What happened to a software company, or a light bulb recycler means nothing—good or bad.
Oxycyte will decide our success or failure!
I thought it was clear, and that no translation was required. But I’ll try again; there is simply no point in analyzing other R/S companies. Their success or failure has NO relevance to OXBO—NONE.
Harping on the past performance of other, totally unrelated, companies adds no value to this discussion. The old adage that “past performance is no guarantee of future results,” is so very true in this case. OXBO has it’s own unique circumstances, and cannot be compared with other companies. If OXBO up-lists, and then hits with oxycyte the shareholdes will be rewarded. IMO, if Oxycyte achieves some major milestones while up-listed the rewards will be far greater then they would be on the OTCBB.
Come on guys, this is dead! They have NO money and NO ONE will lend to, or invest in, this dog. Every word they put into a PR in the last year was total BS. IMO their actions have been unethical and possibly criminal.
Smoke and mirrors and outright lies.
King, lets also call your opinion what it is--just your opinion! I disagree; I see a strategy whereby the company is already up-listed when Oxycyte begins to reach its potential. The benefits to this are obvious.
what?
No, actually i know there are a lot of shares here.
Why are Vatea’s interests different then other investors?
They don’t want OXBO to succeed?
Why are the investors who are pumping money into OXBO evil?
IMO, There are too many conspiracy theories out there.
Assuming Vatea votes yes, and a few other larger investors I know vote yes--I think it is a done deal. I’m not trying to discourage anyone from voting, but all should consider their position in OXBO assuming the split passes.
I’m satisfied that this is a good move, for those of you who can’t live with it, you will be missed :)
At the end of the day it's still about Oxycyte !!!
This is turning into a conspiracy theory message board. Looks like this issue will churn up the investor base a bit. I'll be sticking around to see how it turns out :)
ohhhh, I get it, sarcasm ;)
King, This topic is being scrutinized very carefully, I’m not sure that everyone who disagrees with you is a “fool.” I don’t like that many A/S, but I also don’t think that management will abuse it. After all, they had 100Mil in A/S since last summer and they have acted responsibly. I’ll vote yes, and I don’t see it as being fooled.
I think King (and please correct me if im wrong) views the much larger A/S as instant dilution.
The beauty of these boards is the diversity of opinion. Agree or disagree, try to embrace the diversity! Some days the guy with the other opinion might even get it right.